What do systematic reviews say?

Extra-oral pulp extirpation at day 0 vs Intra-oral pulp extirpation at day 7

• Interventions for treating traumatised permanent front teeth: avulsed (knocked out) and replanted 2019 · Cochrane All outcomes
  Giannetti 2006 did not report this outcome; following email correspondence, authors reported no adverse effects were seen (uncertain whether formally assessed).
  1 study
  GRADE not reported

Hyperbaric oxygen therapy (HBO) following extractions vs penicillin G

• Interventions for preventing osteoradionecrosis of the jaws in adults receiving head and neck radiotherapy 2019 · Cochrane All outcomes

  6 months
  Adverse effects were an outcome of interest in the study conducting this comparison, however no mention was made of the presence or absence of any adverse events
  1 study · 74 participants
  Very low

Hyperbaric oxygen (following replantation) vs control

• Interventions for treating traumatised permanent front teeth: avulsed (knocked out) and replanted 2019 · Cochrane All outcomes
  Chen 2000 did not report this outcome; following email correspondence, authors reported no adverse effects were seen (uncertain whether formally assessed).
  1 study
  GRADE not reported

Thymosin alpha 1 (10-minute soak prior to replantation) vs Normal saline

• Interventions for treating traumatised permanent front teeth: avulsed (knocked out) and replanted 2019 · Cochrane All outcomes
  Loo 2008 did not report this outcome; following email correspondence, authors reported no adverse effects were seen (uncertain whether formally assessed).
  1 study
  GRADE not reported

Clinic‐based intervention vs usual care

The review found no eligible studies for this question.

• Disease management interventions for heart failure 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Multidisciplinary disease management programmes vs usual care

• Disease management interventions for heart failure 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 496 participants
  Moderate

Case management vs usual care

The review found no eligible studies for this question.

• Disease management interventions for heart failure 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Pelvic floor muscle training (PFMT) with urotherapy vs urotherapy alone

The review found no eligible studies for this question.

• Conservative interventions for treating functional daytime urinary incontinence in children 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Voiding education with uroflow feedback and urotherapy vs urotherapy alone

• Conservative interventions for treating functional daytime urinary incontinence in children 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 133 participants
  GRADE not reported

Timer watch plus standard urotherapy vs urotherapy alone

The review found no eligible studies for this question.

• Conservative interventions for treating functional daytime urinary incontinence in children 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Transcutaneous electrical nerve stimulation (TENS) and standard urotherapy vs pelvic floor muscle training (PFMT) with electromyographic biofeedback and standard urotherapy

The review found no eligible studies for this question.

• Conservative interventions for treating functional daytime urinary incontinence in children 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Pelvic floor muscle training (PFMT) with electromyography biofeedback and standard urotherapy vs pelvic floor muscle training without biofeedback but with standard urotherapy

The review found no eligible studies for this question.

• Conservative interventions for treating functional daytime urinary incontinence in children 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Pelvic floor muscle training vs anticholinergics

• Conservative interventions for treating functional daytime urinary incontinence in children 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 47 participants
  Very low

TENS vs anticholinergics

• Conservative interventions for treating functional daytime urinary incontinence in children 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 61 participants
  Very low

Voiding education with uroflowmetry and feedback vs anticholinergics

• Conservative interventions for treating functional daytime urinary incontinence in children 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 64 participants
  GRADE not reported

TENS vs sham TENS

The review found no eligible studies for this question.

• Conservative interventions for treating functional daytime urinary incontinence in children 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs placebo

• Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
  No evidence of a difference in reported adverse events across the three trials (nausea, fever, constipation, diarrhoea, headache, fatigue and others)
  3 studies
  GRADE not reported

Amifostine (intravenous) vs Amifostine (subcutaneous)

• Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
  Increased hypotension with intravenous delivery (20% vs 8%; P = 0.007); skin rash (10% vs 22%; P = 0.012) and local pain at injection site (0% vs 8%; P = 0.001) worse with subcutaneous; inconclusive for…
  1 study
  GRADE not reported

Non-specific immunotherapy (recombinant interleukin-2 or BCG cell wall preparation) plus standard therapy vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Non-specific immunotherapy (recombinant interleukin-2 or BCG cell… showed no clear difference in adverse effects compared with standard therapy alone; GRADE not reported.

• Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes

  24 to 70 months · Moderate to severe chills (BCG-CWP, all grades)
  RR 11.00 [0.67, 179.29]
  1 study · 24 participants
  GRADE not reported
• Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes

  24 to 70 months · Nausea/vomiting (rIL-2, grades >=3)
  RR 3.40 [0.15, 77.34]
  1 study · 30 participants
  GRADE not reported
• Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes

  24 to 70 months · Stomatitis (rIL-2, all grades)
  RR 1.47 [0.75, 2.90]
  1 study · 30 participants
  GRADE not reported

Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… led to higher adverse effects compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported.

• Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes

  40 to 60 months · Skin toxicity (lapatinib, all grades)
  RR 2.02 [1.23, 3.32]
  1 study · 67 participants
  GRADE not reported
• Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes

  40 to 60 months · Gastrointestinal complaints (gefitinib, all grades)
  RR 1.04 [0.98, 1.11]
  1 study · 226 participants
  GRADE not reported
• Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes

  40 to 60 months · Gastrointestinal complaints (lapatinib, all grades)
  RR 15.53 [2.18, 110.55]
  1 study · 67 participants
  GRADE not reported